Listar por autoría "98f3c218-b380-42be-b9c8-fd8b14bc7173"

Mostrando ítems 1-2 de 2

    • openAccess   Changes in myocardial iron content following administration of intravenous iron (Myocardial‐IRON): Study design 

      Miñana, Gema; Cardells, Ingrid; Palau, Patricia; Llàcer, Pau; Facila Rubio, Lorenzo; Almenar, Luis; López‐Lereu, Maria Pilar; Monmeneu, Jose V.; Amiguet, Martina; González, Jessika; Serrano, Alicia; Montagud, Vicente; López‐Vilella, Raquel; Valero, Ernesto; García-Blas, Sergio; Bodí, Vicent; de la Espriella-Juan, Rafael; Sanchis, Juan; Chorro, Francisco J.; Bayés‐Genís, Antoni; Núñez, Julio; Myocardial‐IRON Investigators Wiley (2018)
      Treatment with intravenous ferric carboxymaltose (FCM) has been shown to improve symptoms, functional capacity, and quality of life in patients with heart failure and iron deficiency. However, the underlying mechanisms for ...

    • openAccess   Noninvasive Imaging Estimation of Myocardial Iron Repletion Following Administration of Intravenous Iron: The Myocardial-IRON Trial 

      Núñez, Julio; Miñana, Gema; Cardells, Ingrid; Palau, Patricia; Llàcer, Pau; Facila Rubio, Lorenzo; Almenar-Bonet, Luis; Lopez-Lereu, Maria Pilar; Monmeneu Menadas, Jose Vicente; Amiguet Comins, Martina; González, Jessika; Serrano, Alicia; Montagud, Vicente; López‐Vilella, Raquel; Valero, Ernesto; García-Blas, Sergio; Bodí, Vicent; de la Espriella-Juan, Rafael; Lupón, Josep; Navarro, Jorge; Górriz, José Luis; Sanchis, Juan American Heart Association (2020-02-13)
      Background Intravenous ferric carboxymaltose (FCM) improves symptoms, functional capacity, and quality of life in heart failure and iron deficiency. The mechanisms underlying these effects are not fully understood. The ...